Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.
暂无分享,去创建一个
M. Budoff | K. Kalantar-Zadeh | C. Kovesdy | R. Kilpatrick | J. Kopple | I. Salusky | D. Regidor | C. J. Mcallister | M. Budoff | I B Salusky | K Kalantar-Zadeh | N Kuwae | D L Regidor | C P Kovesdy | R D Kilpatrick | C S Shinaberger | C J McAllister | M J Budoff | J D Kopple | N. Kuwae | C. S. Shinaberger | M. Budoff
[1] K. Martin,et al. Vitamin D analogs: actions and role in the treatment of secondary hyperparathyroidism. , 2004, Seminars in nephrology.
[2] F. Port,et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. , 2005, Kidney international.
[3] Sander Greenland,et al. Multiple‐bias modelling for analysis of observational data , 2005 .
[4] Grace H. Lee,et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] F. Locatelli,et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. , 2004, The New England journal of medicine.
[6] C. Zoccali,et al. Low parathyroid hormone and pentosidine in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[7] J. Bergström,et al. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. , 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] F. Port,et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[9] R. Foley,et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. , 1996, American journal of nephrology.
[10] P. Fein,et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[11] G. Chertow,et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.
[12] R. Elashoff,et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. , 2005, Journal of the American Society of Nephrology : JASN.
[13] R. Foley,et al. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. , 1996, Journal of the American Society of Nephrology : JASN.
[14] S. Greenland,et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[15] K. Kalantar-Zadeh,et al. Normalized protein nitrogen appearance is correlated with hospitalization and mortality in hemodialysis patients with Kt/V greater than 1.20. , 2003, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[16] D. Scharfstein,et al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. , 2004, Journal of clinical epidemiology.
[17] Takashi Akiba,et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] G. Eknoyan,et al. Bone metabolism and disease in chronic kidney disease , 2003 .
[19] N. Powe,et al. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. Choices for Healthy Outcomes in Caring for ESRD. , 2000, Journal of the American Society of Nephrology : JASN.
[20] S. Greenland,et al. Kalantar-Zadeh, K. et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol. Dial. Transplant. 20, 1880-1888 , 2005 .
[21] F. Kronenberg,et al. Prevalence and progression of peripheral arterial calcifications in patients with ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[22] S. Greenland,et al. Reverse Epidemiology of Hypertension and Cardiovascular Death in the Hemodialysis Population: The 58th Annual Fall Conference and Scientific Sessions , 2005, Hypertension.
[23] S. Greenland,et al. Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[24] B. Leistikow. Commentary: Questionable premises, overadjustment, and a smoking/suicide association in younger adult men. , 2003, International journal of epidemiology.
[25] B. Kestenbaum,et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. , 2005, Journal of the American Society of Nephrology : JASN.
[26] P. Raggi,et al. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. , 2002, Kidney international.
[27] S. Massry,et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[28] E. Slatopolsky,et al. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[29] Ajay K. Singh,et al. Complications of chronic kidney disease: anemia, mineral metabolism, and cardiovascular disease. , 2005, The Medical clinics of North America.
[30] M. Marinella. The refeeding syndrome and hypophosphatemia. , 2003, Nutrition reviews.
[31] R. Foley,et al. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. , 2005, Journal of the American Society of Nephrology : JASN.
[32] K. Kalantar-Zadeh,et al. Time-dependent associations between iron and mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[33] Brennan,et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.
[34] S. Greenland,et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.
[35] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[36] J. Kaufman,et al. Epoetin requirements predict mortality in hemodialysis patients. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[37] G. Kaysen,et al. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[38] J T Daugirdas,et al. The post: pre dialysis plasma urea nitrogen ratio to estimate K.t/V and NPCR: validation. , 1989, The International journal of artificial organs.
[39] D. Andress. VITAMIN D IN HEALTH AND DISEASE: Vitamin D Treatment in Chronic Kidney Disease , 2005, Seminars in dialysis.
[40] P. Raggi,et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? , 2002, Journal of the American College of Cardiology.
[41] Keith C. Norris,et al. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[42] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[43] M. Hernán,et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.
[44] K. Kalantar-Zadeh,et al. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[45] Keith C. Norris,et al. Clinical and laboratory features of aluminum-related bone disease: differences between sporadic and "epidemic" forms of the syndrome. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] P. Stenvinkel,et al. Why Do Dialysis Patients Develop a Heart of Stone and Bone of China? , 2005, Blood Purification.